2015 Small Molecule Targeted Protein Degradation Therapies 
Drug Target Review
OCTOBER 4, 2023
Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs.
The Pharma Data
SEPTEMBER 15, 2020
Amgen is a proud sponsor of MBC BioLabs, assisting high-potential and innovative early-stage life science and biotech companies accelerating development of new therapies to improve human health. We look forward to interacting with Amgen ‘s scientific and therapeutic experts to help move Trilomer® therapies into the clinic.
Expert insights. Personalized for you.
125 
Let's personalize your content